Amneal wins FDA nod for generic rivastigmine transdermal patch

Amneal Pharmaceuticals (NYSE:AMRX) said today that it won FDA approval for a generic rivastigmine transdermal patch.

The drug, which is sold under the brand name Exelon, is an acetylcholinesterase inhibitor that is commonly used to treat mild to moderate Alzheimer’s disease and Parkinson’s disease.

Get the full story at our sister site, Drug Delivery Business News.

The post Amneal wins FDA nod for generic rivastigmine transdermal patch appeared first on MassDevice.

from MassDevice http://bit.ly/2AMNDjZ